Acute Graft Versus Host Disease
Welcome,         Profile    Billing    Logout  
 36 Companies   37 Products   37 Products   30 Mechanisms of Action   0 Trials   139 News 


123»
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Trial completion, Enrollment change:  Ruxolitinib for Steroid-refractory GVHD (clinicaltrials.gov) -  Apr 5, 2019   
    P2,  N=75, Completed, 
    Active, not recruiting --> Terminated; Sponsor withdrew support Recruiting --> Completed | N=50 --> 75
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
    Enrollment change, Trial termination:  Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=20, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018 N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
  • ||||||||||  cyclophosphamide / Generic mfg., mycophenolate mofetil / Generic mfg., cytarabine / Generic mfg.
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis (clinicaltrials.gov) -  Jan 23, 2018   
    P4,  N=412, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014 Recruiting --> Completed | Phase classification: P2 --> P4 | N=100 --> 412 | Trial primary completion date: Dec 2017 --> Sep 2017
  • ||||||||||  Biomarker, Enrollment change, Trial withdrawal, Trial primary completion date:  Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD) (clinicaltrials.gov) -  Oct 19, 2017   
    P=N/A,  N=0, Withdrawn, 
    N=25 --> 1 | Recruiting --> Terminated N=75 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2017 --> Oct 2017
  • ||||||||||  mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
    Trial initiation date, Trial primary completion date:  Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT (clinicaltrials.gov) -  Jun 5, 2017   
    P2,  N=3, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Sep 2016 Initiation date: Sep 2009 --> Aug 2006 | Trial primary completion date: May 2011 --> Aug 2010
  • ||||||||||  Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
    Trial completion, Trial primary completion date:  Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) -  May 24, 2017   
    P1/2,  N=14, Completed, 
    Initiation date: Sep 2009 --> Aug 2006 | Trial primary completion date: May 2011 --> Aug 2010 Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017
  • ||||||||||  cyclophosphamide / Generic mfg., mycophenolate mofetil / Generic mfg., cytarabine / Generic mfg.
    Enrollment open, Trial primary completion date:  ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis (clinicaltrials.gov) -  May 16, 2017   
    P2,  N=100, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Dec 2017
  • ||||||||||  neihulizumab (ALTB-168) / AltruBio
    Enrollment change, Trial termination, Trial primary completion date:  A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant (clinicaltrials.gov) -  Mar 30, 2017   
    P1,  N=4, Terminated, 
    Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Dec 2017 N=12 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2016; Re-initiate a new trial per the discussion with FDA
  • ||||||||||  Farydak (panobinostat) / Secura Bio
    Trial completion, Trial primary completion date, Epigenetic controller:  Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) (clinicaltrials.gov) -  Mar 23, 2017   
    P1/2,  N=22, Completed, 
    N=12 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2016; Re-initiate a new trial per the discussion with FDA Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Oct 2015
  • ||||||||||  Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
    Enrollment closed, Enrollment change:  Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) -  Mar 8, 2017   
    P1/2,  N=14, Active, not recruiting, 
    Active, not recruiting --> Terminated; Terminated early at the Sponsor's discretion, not due to safety concerns. Recruiting --> Active, not recruiting | N=24 --> 14
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    New P2 trial:  Ruxolitinib for Steroid-refractory GVHD (clinicaltrials.gov) -  Dec 20, 2016   
    P2,  N=50, Recruiting, 
  • ||||||||||  Remicade (infliximab) / J&J, Simulect (basiliximab) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date:  Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease (clinicaltrials.gov) -  Apr 27, 2016   
    P2,  N=10, Active, not recruiting, 
    Trial primary completion date: Jun 2016 --> Nov 2016 Recruiting --> Active, not recruiting | N=44 --> 10 | Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Combination therapy:  Photopheresis for the Treatment of Acute Graft Versus Host Disease (clinicaltrials.gov) -  Feb 10, 2016   
    P2,  N=81, Completed, 
    Active, not recruiting --> Completed | N=22 --> 27 Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2016